Trial · NCT00103740
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Who Had Therapeutic Response at 6 Months | Zoledronic Acid and Placebo to Risedronate | 84 | participants | ||
| Number of Patients Who Had Therapeutic Response at 6 Months | Risedronate and Placebo to Zoledronic Acid | 67 | participants | ||
| Relative Change in Serum Alkaline Phosphatase in U/L at Day 28 | Zoledronic Acid and Placebo to Risedronate | -49.1 | Standard Deviation 14.55 | percent change | |
| Relative Change in Serum Alkaline Phosphatase in U/L at Day 28 | Risedronate and Placebo to Zoledronic Acid | -24.3 | Standard Deviation 18.19 | percent change | |
| Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10 | Zoledronic Acid and Placebo to Risedronate | -74.2 | Standard Deviation 123.73 | percent change | |
| Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10 | Risedronate and Placebo to Zoledronic Acid | -40.1 | Standard Deviation 34.70 | percent change | |
| Relative Change in Urine α-CTx in ug/mmol at Day 10 | Zoledronic Acid and Placebo to Risedronate | -87.5 | Standard Deviation 39.33 | percent change | |
| Relative Change in Urine α-CTx in ug/mmol at Day 10 | Risedronate and Placebo to Zoledronic Acid | -28.7 | Standard Deviation 68.22 | percent change | |
| Time to First Therapeutic Response | Zoledronic Acid and Placebo to Risedronate | 64 | Inter-Quartile Range 33 to 65 | days | |
| Time to First Therapeutic Response | Risedronate and Placebo to Zoledronic Acid | 91 | Inter-Quartile Range 64 to 181 | days | |
| Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 | Zoledronic Acid and Placebo to Risedronate | 8 | participants | ||
| Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 | Risedronate and Placebo to Zoledronic Acid | 1 | participants | ||
| Change in Pain Severity at Day 182 | Zoledronic Acid and Placebo to Risedronate | -0.5 | Standard Deviation 1.74 | units on a scale | |
| Change in Pain Severity at Day 182 | Risedronate and Placebo to Zoledronic Acid | -0.1 | Standard Deviation 2.02 | units on a scale | |
| Change in Pain Interference at Day 182 | Zoledronic Acid and Placebo to Risedronate | -0.5 | Standard Deviation 1.97 | units on a scale | |
| Change in Pain Interference at Day 182 | Risedronate and Placebo to Zoledronic Acid | 0.0 | Standard Deviation 1.89 | units on a scale | |
| Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period | Zoledronic Acid and Placebo to Risedronate | 10 | 2218 to NA | participants | |
| Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period | Risedronate and Placebo to Zoledronic Acid | 42 | 344 to 1605 | participants | |
| Number of Participants With a Partial Disease Relapse During the Extended Observation Period | Zoledronic Acid and Placebo to Risedronate | 9 | 2218 to NA | participants | |
| Number of Participants With a Partial Disease Relapse During the Extended Observation Period | Risedronate and Placebo to Zoledronic Acid | 37 | 373 to 1652 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00103740/results